Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of TQB2450 plus platinum chemotherapy followed by TQB2450 plus anlotinib versus tislelizumab plus platinum chemotherapy in advanced non-squamous NSCLC
CTR20220484Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib, tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jan 2022; status: active.
02
Drugs
benmelstobartanlotinibtislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220484.